Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors

Farmaco

Volumn 60, Issue 1, 2005, Pages 7-13

  Cusan, Claudia ^a   Spalluto, Giampiero ^a   Prato, Maurizio ^a   Adams, Michael ^b   Bodensieck, Antje ^b   Bauer, Rudolf ^b   Tubaro, Aurelia ^a   Bernardi, Paolo ^c   Da Ros, Tatiana ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cyclooxygenase; Dual inhibitors; Lipoxygenase; Phenidone derivatives

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DECANOIC ACID (3 OXO 1 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)AMIDE; INDOMETACIN; LIPOXYGENASE INHIBITOR; N (3 OXO 1 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL) 2 (2,4,6 TRIBROMOPHENYL)ACETAMIDE; N (3 OXO 1 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)BENZAMIDE; N (3 OXO 1 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)PROPIONAMIDE; N (3 OXO 1 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)SUCCINAMIC ACID METHYL ESTER; PENTANOIC ACID (3 OXO 1 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)AMIDE; PHENIDONE; SUCCINIC ACID 4 (3 METHOXYCARBONYLPROPIONYLAMINO) 1 PHENYL 1H PYRAZOL 3 YLMETHYL ESTER; UNCLASSIFIED DRUG; ZILEUTON;

AMINO ACID SUBSTITUTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEDICAL LITERATURE; PROTON NUCLEAR MAGNETIC RESONANCE;

CYCLOOXYGENASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOXYGENASE INHIBITORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12344330678     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2004.09.002     Document Type: Article

References (23)

1. G. Ara, and B.A. Teicher Cyclooxygenase and lipoxygenase inhibitors in cancer therapy Prostagl. Leukotr. Ess. Fatty Acids 54 1996 3 16
2. S.E. Wenzel New approaches to anti-inflammatory therapy for asthma Am. J. Med. 104 1998 287 300
3. R.N. Young Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized Eur. J. Med. Chem. 34 1999 671 685
4. S.D. Brain, and T.J. Williams Leukotrienes and inflammation Pharmacol. Ther. 46 1990 57 66
5. C. Charlier, and C. Michaux Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs Eur. J. Med. Chem 38 2003 645 659
6. T. Koshino, S. Takano, T. Houjo, Y. Sano, K. Kudo, and H. Kimara Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein mRNAs in the peripheral blood leukocytes of asthmatics Biochem. Biophys. Res. Commun. 247 1998 510 513
7. J.R. Vane, and R.M. Botting Mechanism of action of nonsteroidal anti-inflammatory drugs Am. J. Med. 104 1998 2S 8S
8. J.R. Vane, Y.S. Bakhle, and R.M. Bottin Cyclooxygenases 1 and 2 Annu. Rev. Pharmacol. Toxicol. 38 1998 97 120
9. J. Claria Cyclooxygenase-2 biology Curr. Pharm. Des 9 2003 2177 2190
10. M.M. Goldenberg Celecoxib, a selective cyclooxygenase-2. Inhibitor for the treatment of rheumatoid arthritis and osteoarthritis Clin. Ther. 21 1999 1497 1513
11. D. Penzo, V. Petronilli, A. Angelin, C. Cusan, R. Colonna, L. Scorrano, F. Pagano, M. Prato, F. Di:Lisa, and P. Bernardi Arachidonic acid released by phospholipase A2 activation triggers Ca2+-dependent apoptosis through the mitochondrial pathway J. Biol. Chem 279 2004 25219 25225
12. L. Scorrano, D. Penzo, V. Petronilli, F. Pagano, and P. Bernardi Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha apoptotic signalling J. Biol. Chem 276 2001 12035 12040
13. V. Petronilli, D. Penzo, L. Scorrano, P. Bernardi, and F. Di:Lisa The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ J. Biol. Chem 276 2001 12030 12034
14. A. Gugliucci, L. Ranzato, L. Scorrano, R. Colonna, V. Petronilli, C. Cusan, M. Prato, M. Mancini, F. Pagano, and P. Bernardi Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors J. Biol. Chem 277 2002 31789 31795
15. X. de:Leval, F. Juĺmont, J. Delarge, B. Pirotte, and J.-M. Dogń New trends in dual 5-LOX/COX inhibition Curr. Med. Chem 9 2002 941 962
16. D. Hlasta, F.B. Casey, E.W. Ferguson, S.J. Gangell, M.R. Heimann, and E.P. Jaeger 5-Lipoxygenase inhibitors: the synthesis and structure-activity relationships of a series of 1-phenyl-3-pyrazolidinones J. Med. Chem. 34 1991 1560 1570
17. P.A. Bhatia, C.D.W. Brooks, A. Basha, J.D. Ratajczyk, B.P. Gunn, and J.B. Bouska 5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones J. Med. Chem. 39 1996 3938 3950
18. C. Ghiglieri-Bertez, C. Coquelet, A. Alazet, and C. Bonne Dual inhibitors of the cyclooxygenase and lipoxygenase pathways: synthesis and activity of hydrazone derivatives Eur. J. Med. Chem. 22 1987 147 152
19. S.W. Wright, R.R. Harris, J.S. Kerr, A.M. Green, D.J. Pinto, and E.M. Bruin Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis J. Med. Chem. 35 1992 4061 4068
20. S. Pietra Ricerche sulla cianalchilazione Boll. Scient. Fac. Chim. Ind. Bo. 11 1953 78 80
21. E. Moczar, and L. Mester Notes sur la structure des d́riv́s de la ph́nyl-1 pyrazolone-3 1962 Bull. Soc. Chim. Fr 1707 1708
22. C. Harries, and G. Loth Zur constitution der 1-Phenylpyrazolone Ber 29 1896 513 529
23. E. Reininger, and R. Bauer New PGHS-1 and -2 microtiter assays for the screening of herbal drugs and in vitro inhibition of PGHS-isoenzymes by polyunsaturated fatty acids from Platycodi radix Phytomedicine 2004 (in press)